HK1132505A1 - Thiazole pyrazolopyrimidines as crf1 receptor antagonists - Google Patents

Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Info

Publication number
HK1132505A1
HK1132505A1 HK10100143.4A HK10100143A HK1132505A1 HK 1132505 A1 HK1132505 A1 HK 1132505A1 HK 10100143 A HK10100143 A HK 10100143A HK 1132505 A1 HK1132505 A1 HK 1132505A1
Authority
HK
Hong Kong
Prior art keywords
receptor antagonists
crf1 receptor
pyrazolopyrimidines
thiazole
thiazole pyrazolopyrimidines
Prior art date
Application number
HK10100143.4A
Other languages
English (en)
Inventor
Zhaogen Chen
Chafiq Hamdouchi Hamdouchi
Erik James Hembre
Philip Arthur Hipskind
Jason Kenneth Myers
Takako Takakuwa
James Lee Toth
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1132505(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1132505A1 publication Critical patent/HK1132505A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK10100143.4A 2006-09-20 2010-01-08 Thiazole pyrazolopyrimidines as crf1 receptor antagonists HK1132505A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82626406P 2006-09-20 2006-09-20
PCT/US2007/078605 WO2008036579A1 (fr) 2006-09-20 2007-09-17 Thiazole pyrazolopyrimidines convenant comme antagonistes du récepteur du crf1

Publications (1)

Publication Number Publication Date
HK1132505A1 true HK1132505A1 (en) 2010-02-26

Family

ID=38924802

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10100143.4A HK1132505A1 (en) 2006-09-20 2010-01-08 Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Country Status (34)

Country Link
US (1) US8030304B2 (fr)
EP (1) EP2094709B1 (fr)
JP (1) JP5161226B2 (fr)
KR (1) KR101088239B1 (fr)
CN (1) CN101516887B (fr)
AR (1) AR062886A1 (fr)
AT (1) ATE481405T1 (fr)
AU (1) AU2007297421B2 (fr)
BR (1) BRPI0717023B8 (fr)
CA (1) CA2663511C (fr)
CL (1) CL2007002693A1 (fr)
CR (1) CR10682A (fr)
CY (1) CY1110854T1 (fr)
DE (1) DE602007009305D1 (fr)
DK (1) DK2094709T3 (fr)
EA (1) EA015179B1 (fr)
ES (1) ES2350282T3 (fr)
HK (1) HK1132505A1 (fr)
HR (1) HRP20100516T1 (fr)
IL (1) IL197614A (fr)
MA (1) MA30798B1 (fr)
MX (1) MX2009003125A (fr)
MY (1) MY146388A (fr)
NO (1) NO20091489L (fr)
NZ (1) NZ575572A (fr)
PE (1) PE20081377A1 (fr)
PL (1) PL2094709T3 (fr)
PT (1) PT2094709E (fr)
RS (1) RS51545B (fr)
SI (1) SI2094709T1 (fr)
TN (1) TN2009000095A1 (fr)
TW (1) TWI402269B (fr)
UA (1) UA96458C2 (fr)
WO (1) WO2008036579A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
ES2397509T3 (es) * 2008-10-02 2013-03-07 Eli Lilly & Company Compuestos de tiazolil-pirazolopirimidina como intermedios sintéticos y procedimientos de síntesis relacionados
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP3096756B1 (fr) * 2014-01-21 2024-06-12 Neurocrine Biosciences, Inc. Antagonistes du récepteur crf1 pour le traitement de l'hyperplasie adrénale congénitale
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
CN109906222B (zh) 2016-09-07 2023-08-01 加利福尼亚大学董事会 减少p-tau并且改善认知的变构促肾上腺皮质激素释放因子受体1(crfr1)拮抗剂
CN110997667A (zh) * 2017-08-14 2020-04-10 云杉生物科学公司 促肾上腺皮质激素释放因子受体拮抗剂
WO2019036503A1 (fr) * 2017-08-14 2019-02-21 Spruce Biosciences, Inc. Antagonistes du récepteur du facteur de libération de la corticotropine
BR112020024062A2 (pt) * 2018-04-27 2021-02-09 Spruce Biosciences, Inc. métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
CN109134481B (zh) * 2018-08-07 2021-05-14 中山大学 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
EP3986416A4 (fr) * 2019-07-19 2023-06-28 Spruce Biosciences, Inc. Méthodes de traitement de l'hyperplasie surrénale congénitale
TW202134241A (zh) * 2019-12-04 2021-09-16 美商紐羅克里生物科學有限公司 Ｃｒｆ受體拮抗劑及使用方法
GR1010096B (el) * 2020-07-02 2021-10-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
CN116322544A (zh) * 2020-08-12 2023-06-23 云杉生物科学公司 用于治疗多囊卵巢综合征的方法和组合物
US20240024330A1 (en) 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
CA3235958A1 (fr) * 2021-11-19 2023-05-25 Spruce Biosciences, Inc. Composition cristalline de tildacerfont et ses methodes d'utilisation et de preparation
WO2023163945A1 (fr) * 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Traitement de l'hyperplasie surrénale congénitale et du syndrome des ovaires polykystiques

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124015C1 (ru) 1992-12-17 1998-12-27 Пфайзер Инк. Производные пирроло [2,3-d] пиримидинов, фармацевтическая композиция, пирроло [2,3-d] пиримидины, производные пиррола
CN1090189C (zh) 1996-02-07 2002-09-04 詹森药业有限公司 吡唑并嘧啶类化合物
SI9720045B (sl) * 1996-07-24 2008-02-29 Bristol Myers Squibb Pharma Co Azolo triazini in pirimidini
EA006626B1 (ru) 1996-07-24 2006-02-24 Дюпон Фармасьютикалз Компани Азолопиримидины, фармацевтическая композиция и способ лечения
HUP9903965A3 (en) 1996-08-28 2002-02-28 Pfizer Substituted 6,5-hetero-bicyclic derivatives
EP1040831A3 (fr) * 1999-04-02 2003-05-02 Pfizer Products Inc. Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
WO2000059908A2 (fr) * 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines antagonistes de corticoliberine (crf)
EA200200421A1 (ru) 1999-09-30 2002-10-31 Ньюроджен Корпорейшн АМИНОЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]-1,5-ПИРИМИДИНЫ И ПИРАЗОЛО[1,5-a]-1,3,5-ТРИАЗИНЫ
MXPA03008185A (es) * 2001-03-13 2004-01-29 Bristol Myers Squibb Pharma Co 4-(2-butilamino)-2, 7-dimetil-8 -(2-metil-6-metoxipirid -3-il) pirazol-[1, 5-a]-1, 3, 5-triazina, sus enantiomeros y sales farmaceuticamente aceptables como ligandos del receptor del factor de liberacion de corticotropina.
JP4926720B2 (ja) * 2003-12-22 2012-05-09 スミスクライン ビーチャム （コーク） リミテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法

Also Published As

Publication number Publication date
DK2094709T3 (da) 2010-12-06
EA015179B1 (ru) 2011-06-30
US20100222339A1 (en) 2010-09-02
CN101516887A (zh) 2009-08-26
BRPI0717023A2 (pt) 2014-03-11
EA200970303A1 (ru) 2009-10-30
BRPI0717023B8 (pt) 2021-05-25
EP2094709A1 (fr) 2009-09-02
CA2663511A1 (fr) 2008-03-27
TWI402269B (zh) 2013-07-21
PE20081377A1 (es) 2008-09-18
RS51545B (en) 2011-06-30
AR062886A1 (es) 2008-12-10
NO20091489L (no) 2009-04-16
TN2009000095A1 (en) 2010-08-19
IL197614A (en) 2012-10-31
PL2094709T3 (pl) 2011-02-28
MY146388A (en) 2012-08-15
JP5161226B2 (ja) 2013-03-13
AU2007297421A1 (en) 2008-03-27
EP2094709B1 (fr) 2010-09-15
UA96458C2 (ru) 2011-11-10
ES2350282T3 (es) 2011-01-20
CL2007002693A1 (es) 2008-04-18
ATE481405T1 (de) 2010-10-15
US8030304B2 (en) 2011-10-04
MX2009003125A (es) 2009-05-28
KR101088239B1 (ko) 2011-11-30
PT2094709E (pt) 2010-10-04
CY1110854T1 (el) 2015-06-10
NZ575572A (en) 2011-10-28
WO2008036579A1 (fr) 2008-03-27
SI2094709T1 (sl) 2011-01-31
IL197614A0 (en) 2009-12-24
AU2007297421B2 (en) 2012-03-08
CR10682A (es) 2009-08-13
CN101516887B (zh) 2011-11-02
HRP20100516T1 (hr) 2010-10-31
BRPI0717023B1 (pt) 2019-11-19
MA30798B1 (fr) 2009-10-01
TW200821312A (en) 2008-05-16
JP2010504344A (ja) 2010-02-12
DE602007009305D1 (de) 2010-10-28
CA2663511C (fr) 2012-12-04
KR20090052366A (ko) 2009-05-25

Similar Documents

Publication Publication Date Title
HK1132505A1 (en) Thiazole pyrazolopyrimidines as crf1 receptor antagonists
IL226486A (en) Converted pyrazolopyrimidine compounds
PL2004654T3 (pl) Pochodne pirazolopirymidyny do stosowania jako antagonisty kinazy
IL201112A0 (en) Thiazolidine derivatives as orexin receptor antagonists
IL194583A0 (en) Imidazo compounds
EP2099454A4 (fr) Aminopyrrolidines utilisés en tant qu'antagonistes du récepteur de la chimiokine
ZA200708028B (en) Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists
EP2079467A4 (fr) Composés bicycliques antidiabétiques
ZA201002334B (en) Imidazo
ZA200706353B (en) Pyrazolo-pyrimidine derivatives as mGluR2 antagonists
EP2093337A4 (fr) Pièce polyvalente
ZA200901124B (en) Quinuclidine derivatives as M3 antagonists
ZA200906812B (en) Crig antagonists
EP2054434A4 (fr) Antagonistes vis-à-vis de la myostatine
SI2069310T1 (sl) Sulfonilpirazolin-1-karboksamidinski derivati kot 5-HT6 antagonisti
IL211030A0 (en) Pyrazolo [5,1-b] oxazole derivatives as crf1 antagonists
SI2004654T1 (sl) Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
GB0613737D0 (en) Retroreflector
IL202339A0 (en) Azacyclylbenzamide derivatives as histamine-3 antagonists
GB0612063D0 (en) Railing
ZA200903523B (en) Poly-TLR antagonist
HK1129105A1 (en) Pyrazolo
GB0611451D0 (en) Cellular antagonist
GB0724654D0 (en) Prolactin antagonist
EP2139329A4 (fr) Hétérocycles à base d'imidazo novateurs

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150917

ARF Application filed for restoration

Effective date: 20160622